A Phase 2/3 interventional study of B244 and Placebo in Acne Vulgaris, sponsored by AOBiome LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-16.
Sponsored by AOBiome LLC · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 93rd largest by enrollment of the 353 interventional ones that give a count, is one of 34 that started in 2016, is one of 6 in phase 2/3, and was the 208th registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
Sagimet Biosciences Inc. · Sites in United States, Australia
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 34 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 372 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 353 interventional studies, 59 across the 19 observational. Of the 322 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
286 of 373 have an industry lead sponsor. The 10 most frequent:
AOBiome LLC is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AOBiome LLC has 3 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
9 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
| NCT07896486Weill Medical College of Cornell UniversityEvaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation | 2027-01-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 373 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.
This is a Phase IIb/III, randomized, double blinded, decentralized clinical trial evaluating the safety, tolerability, and efficacy of B244 compared to placebo in the treatment of acne vulgaris
1.1. Primary Objectives
To assess the efficacy of B244 in participants with mild to moderate acne vulgaris from baseline to week 12 (end of treatment) by:
i) Reduction in inflammatory and non-inflammatory lesion count ii) IGA success
1.2. Secondary Objectives 1. To evaluate the efficacy of B244 in participants with mild to moderate acne vulgaris from baseline to weeks 2, 4, 8, and 16: i) Reduction in inflammatory and non-inflammatory lesion count ii) IGA success iii) Improvement in patient reported quality of life score using the Skindex-16 questionnaire
1.3. Exploratory Objective
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants eligible for enrollment in the study must meet all the following criteria:
Clinical diagnosis of mild to moderate facial acne vulgaris defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
B244 dose administered in a 1:1 (active vs placebo) ratio
Biological: B244
Placebo dose administered in a 1:1 (active vs placebo) ratio
Biological: Placebo
4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
Number of Participants With Treatment RelatedAdverse Events
Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.
Time frame: 16 weeks
Change in Inflammatory and Non-inflammatory Lesion Count
Lesion counting was performed using the digital photos taken by participants and stored inside the study mobile platform by trained personnel only. Every effort was made to have the counting and clinical evaluation done by the same evaluator for a given participant. Lesions under the jaw line or behind the hairline (including eyebrows) were not included in the counts. Papules, pustules, cysts and nodules were classified as inflammatory acne lesions, and open and closed comedones were classified as non-inflammatory lesions.
Time frame: 12 weeks
Number of Participants Demonstrating Efficacy Measured by Investigator Global Assessment Success
IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). IGA success was defined as a post-baseline score of 0 or 1 (yes=success, no=no success).
Time frame: 12 weeks
Change in Inflammatory and Non-inflammatory Lesion Count by Week
Lesion counting was performed using the digital photos taken by participants and stored inside the study mobile platform by trained personnel only. Every effort was made to have the counting and clinical evaluation done by the same evaluator for a given participant. Lesions under the jaw line or behind the hairline (including eyebrows) were not included in the counts. Papules, pustules, cysts and nodules were classified as inflammatory acne lesions, and open and closed comedones were classified as non-inflammatory lesions.
Time frame: Baseline to weeks 2, 4, 8, 12 and 16
Number of Participants Demonstrating Efficacy Measured Investigator Global Assessment Score by Week
IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). IGA success was defined as a post-baseline score of 0 or 1 (yes=success, no=no success).
Time frame: Baseline to weeks 2, 4, 8, 12 and 16
Change in Patient Reported Quality of Life Score Using the Skindex-16 Questionnaire
The Skindex 16 questionnaire was assigned to subjects to examine the relationship between the subject's skin health and quality of life. Subjects scored 16 questions from 0 to 6 (0=never bothered, 6=always bothered). Total scores could range between 0 to 96, where a higher score is associated with a worse quality of life.
Time frame: Baseline to weeks 2, 4, 8, 12 and 16
To Evaluate Facial Skin Microbiota
Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.
Time frame: baseline, week 4, week 8, week 12, and week 16
| Milestone | B244 Arm | Placebo Arm |
|---|---|---|
| Started | 186 | 186 |
| Completed | 152 | 148 |
| Not completed | 34 | 38 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Physician decision | 5 | 7 |
| Withdrew: Lost to follow-up | 15 | 8 |
| Withdrew: Withdrawal by subject | 10 | 21 |
| Withdrew: Other | 2 | 1 |
Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.
| Participants | B244 Arm | Placebo Arm |
|---|---|---|
| At Least 1 Treatment Related TEAE | 10 | 9 |
| At Least 1 Treatment Related SAE | 0 | 0 |
Lesion counting was performed using the digital photos taken by participants and stored inside the study mobile platform by trained personnel only. Every effort was made to have the counting and clinical evaluation done by the same evaluator for a given participant. Lesions under the jaw line or behind the hairline (including eyebrows) were not included in the counts. Papules, pustules, cysts and nodules were classified as inflammatory acne lesions, and open and closed comedones were classified as non-inflammatory lesions.
| lesions | B244 Arm | Placebo Arm |
|---|---|---|
| Change in Inflammatory Lesion Count from Baseline to Week 12 | -4.8 ± 10.1 | -3.9 ± 9.13 |
| Change in Non-Inflammatory Lesion Count from Baseline to Week 12 | -4.0 ± 22.0 | -4.9 ± 20.9 |
IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). IGA success was defined as a post-baseline score of 0 or 1 (yes=success, no=no success).
| Participants | B244 Arm | Placebo Arm |
|---|---|---|
| Yes | 25 | 12 |
| No | 127 | 137 |
Lesion counting was performed using the digital photos taken by participants and stored inside the study mobile platform by trained personnel only. Every effort was made to have the counting and clinical evaluation done by the same evaluator for a given participant. Lesions under the jaw line or behind the hairline (including eyebrows) were not included in the counts. Papules, pustules, cysts and nodules were classified as inflammatory acne lesions, and open and closed comedones were classified as non-inflammatory lesions.
| lesions | B244 Arm | Placebo Arm |
|---|---|---|
| Change in Inflammatory Lesion Count from Baseline to Week 2 | -1.5 ± 10.9 | -1.3 ± 9.94 |
| Change in Inflammatory Lesion Count from Baseline to Week 4 | -0.8 ± 10.46 | -0.8 ± 9.49 |
| Change in Inflammatory Lesion Count from Baseline to Week 8 | -3.3 ± 9.94 | -3.1 ± 8.75 |
| Change in Inflammatory Lesion Count from Baseline to Week 12 | -4.8 ± 10.1 | -3.9 ± 9.13 |
| Change in Inflammatory Lesion Count from Baseline to Week 16 | -3.2 ± 20.6 | -4.0 ± 11.4 |
| Change in Non-Inflammatory Lesion Count from Baseline to Week 2 | -0.9 ± 17.1 | -2.1 ± 18.4 |
| Change in Non-Inflammatory Lesion Count from Baseline to Week 4 | -1.5 ± 21.3 | -4.6 ± 19.1 |
| Change in Non-Inflammatory Lesion Count from Baseline to Week 8 | -4.1 ± 20.4 | -5.8 ± 17.4 |
| Change in Non-Inflammatory Lesion Count from Baseline to Week 12 | -4.0 ± 22.0 | -4.9 ± 20.9 |
| Change in Non-Inflammatory Lesion Count from Baseline to Week 16 | -6.4 ± 23.2 | -6.1 ± 21.7 |
IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). IGA success was defined as a post-baseline score of 0 or 1 (yes=success, no=no success).
| Participants | B244 Arm | Placebo Arm |
|---|---|---|
| Week 2 — Yes | 12 | 13 |
| Week 2 — No | 162 | 157 |
| Week 4 — Yes | 9 | 13 |
| Week 4 — No | 159 | 153 |
| Week 8 — Yes | 16 | 10 |
| Week 8 — No | 144 | 150 |
| Week 12 — Yes | 25 | 12 |
| Week 12 — No | 127 | 137 |
| Week 16 — Yes | 12 | 17 |
| Week 16 — No | 140 | 131 |
The Skindex 16 questionnaire was assigned to subjects to examine the relationship between the subject's skin health and quality of life. Subjects scored 16 questions from 0 to 6 (0=never bothered, 6=always bothered). Total scores could range between 0 to 96, where a higher score is associated with a worse quality of life.
| score on a scale | B244 Arm | Placebo Arm |
|---|---|---|
| Change from Baseline to Week 2 | -0.6 ± 1.05 | -1.6 ± 0.97 |
| Change from Baseline to Week 4 | -0.7 ± 1.10 | -0.7 ± 1.12 |
| Change from Baseline to Week 8 | -0.6 ± 1.23 | -0.7 ± 1.16 |
| Change from Baseline to Week 12 | -0.7 ± 1.16 | -0.6 ± 1.17 |
| Change from Baseline to Week 16 | -0.8 ± 1.16 | -0.7 ± 1.17 |
Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.
No measurements were reported for this outcome.
Collected over Baseline to Week 16.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B244 Arm | 0/181 (0%) | 3/181 (1.7%) | 39/181 (21.5%) |
| Placebo Arm | 0/179 (0%) | 2/179 (1.1%) | 42/179 (23.5%) |
| Event | B244 Arm | Placebo Arm |
|---|---|---|
| PyrexiaGeneral disorders | 0/181 | 1/179 |
| GastroenteritisGastrointestinal disorders | 0/181 | 1/179 |
| NephrolithiasisRenal and urinary disorders | 1/181 | 1/179 |
| DepressionPsychiatric disorders | 1/181 | 0/179 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/181 | 0/179 |
| Event | B244 Arm | Placebo Arm |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 7/181 | 6/179 |
| Dry skinSkin and subcutaneous tissue disorders | 2/181 | 4/179 |
| Pharyngitis streptococcalInfections and infestations | 0/181 | 3/179 |
| Upper respiratory tract infectionInfections and infestations | 3/181 | 1/179 |
| Psychiatric disordersInvestigations | 3/181 | 0/179 |
| DepressionInvestigations | 3/181 | 0/179 |
| Ear infectionInfections and infestations | 1/181 | 2/179 |
| PneumoniaInfections and infestations | 0/181 | 2/179 |
| SinusitisInfections and infestations | 2/181 | 2/179 |
| Urinary tract infectionInfections and infestations | 1/181 | 2/179 |
Efficacy analysis set: all subjects who received at least 1 application of IP
| Age, Customized(Participants) | B244 Arm | Placebo Arm | Total |
|---|---|---|---|
| 18 to <30 years | 126 | 122 | 248 |
| 30 to <65 years | 55 | 57 | 112 |
| Sex: Female, Male(Participants) | B244 Arm | Placebo Arm | Total |
|---|---|---|---|
| Female | 95 | 92 | 187 |
| Male | 86 | 87 | 173 |
| Ethnicity (NIH/OMB)(Participants) | B244 Arm | Placebo Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 39 | 37 | 76 |
| Not Hispanic or Latino | 137 | 141 | 278 |
| Unknown or Not Reported | 5 | 1 | 6 |
| Race (NIH/OMB)(Participants) | B244 Arm | Placebo Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 27 | 21 | 48 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 19 | 9 | 28 |
| White | 107 | 133 | 240 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 28 | 16 | 44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Jul 2017, 11 months.
Results were first posted in Sep 2022, 5 years 1 month after primary completion. A results delay was requested in Jul 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitrosomonas eutropha D23
AOBiome LLC